5082W-11 A study of the effectiveness and safety of Epratuzumab in Systemic Lupus Erythematosis(SLE)

A study of the effectiveness and safety of Epratuzumab in Systemic Lupus Erythematosis (SLE) (EMBODY)

Type of Study
Rheumatology - Systemic Lupus Erythematosis (SLE)
Location
First Hill Campus
Short Description

The primary objective of the study is to confirm the clinical effectiveness of epratuzumab in the treatment of subjects with moderate to severe general SLE despite standard of care treatments (ie, corticosteroids, and potentially antimalarials and immunosuppressants).

Status
Open
Principal Investigator
Philip J. Mease, MD
Eligibility Notes

You must meet the study requirements, including (but not limited to):

  • At least 18 years old.
  • Have SLE diagnosed by a physician.
  • Have active moderate to severe SLE disease activity


You cannot (but not only) have:

  • Active, severe, SLE disease activity in certain body systems
  • A history of chronic infections
  • A particularly high risk of significant infection
Start Date
5/25/2011
Contact Name
Sephren Barrow
Phone
206-386-6248
Alternate Phone
206-386-3201
Email
Sephren.Barrow@swedish.org
Alternate Email
Allison.Everett@swedish.org